Abstract:Somatic ACE (EC 3.4.15.1), a Zn(II) metalloproteinase, is composed of functionally active N and C domains resulting from tandem gene duplication. Despite the high degree of sequence similarity between the two domains, they differ in substrate and inhibitor specificity and in their activation by chloride ions. Because of the critical role of ACE in cardiovascular and renal diseases, both domains are attractive targets for drug design. Putative structural models have been generated for the interactions of ACE inhibitors (lisinopril, captoril, enalaprilat, keto-ACE, ramiprilat, quinaprilat, peridoprilat, fosinoprilat, and RXP 407) with both the ACE_C and the ACE_N domains. Inhibitor-domain selectivity was interpreted in terms of residue alterations observed in the four subsites of the binding grooves of the ACE_C/ACE_N domains (S1: V516/N494, V518/T496, S2: F391/Y369, E403/R381, S1': D377/Q355, E162/D140, V379/S357, V380/T358, and S2': D463/E431, T282/S260). The interactions governing the ligand-receptor recognition process in the ACE_C domain are: a salt bridge between D377, E162, and the NH(2) group (P1' position), a hydrogen bond of the inhibitor with Q281, the presence of bulky hydrophobic groups in the P1 and P2' sites, and a stacking interaction of F391 with a benzyl group in the P2 position. In ACE_N these interactions are: hydrogen bonds of the inhibitor with E431, Y369, and R381, and a salt bridge between the carboxy group in the P2 position of the inhibitor and R500. The calculated complexes were evaluated for their consistency with structure-activity relationships and site-directed mutagenesis data. A comparison between the calculated interaction free energies and the experimentally observed biological activities was also made. Pharmacophore refinement was achieved at an atomic level, and might provide an improved basis for structure-based rational design of second-generation, domain-selective inhibitors.

Advances in the structural basis for Angiotensin-1 converting enzyme (ACE) inhibitors

Rediscovering ACE: Novel Insights into the Many Roles of the Angiotensin-Converting Enzyme

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors

Progress on the Treatment for Hypertension of Epoxide Hydrolase and Its Mechanisms

Insight into the interactive residues between two domains of human somatic Angiotensin-converting enzyme and Angiotensin II by MM-PBSA calculation and steered molecular dynamics simulation

Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Angiotensin-converting enzyme: a well-known stranger. Part I

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Beyond ACE inhibition: new developments in drug therapy for hypertension

Aldosterone and aldosterone synthase inhibitors in cardiorenal disease

Progress of Pathophysiological Mechanism of Angiotensin-Converting Enzyme 2 in Treating Pulmonary Arterial Hypertension

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine

Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention

Angiotensin I-converting enzyme inhibitory peptide: an emerging candidate for vascular dysfunction therapy

A General Introduction of Clinical Application of Angiotension Converting Enzyme Inhibitors

Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography